NDA 204569 · Merck Sharp Dohme
Belsomra
Suvorexant · Oral · Orexin Receptor Antagonist
NovelLast checked: Nov 19, 2026Latest source record: Mar 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Aug 13, 2014
Approved uses
2
Original approval plus efficacy supplements
Registered trials
69
7 Phase 3, 11 recruiting
FAERS reports
13,031
4,515 serious, 718 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 10, 2025.
BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. BELSOMRA is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance ( 1 ).
Mechanism: The mechanism of action of suvorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors. The orexin neuropeptide signaling system plays a role in wakefulness. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 29, 2020 Supplement 6 · Efficacy LetterLabel
- Aug 13, 2014 Original approval · Type 1 - New Molecular Entity NovelReviewSummary ReviewLabel
4 products under this application
- BELSOMRA · SUVOREXANT 20MG · TABLET, ORAL · Prescription
- BELSOMRA · SUVOREXANT 10MG · TABLET, ORAL · Prescription
- BELSOMRA · SUVOREXANT 15MG · TABLET, ORAL · Prescription
- BELSOMRA · SUVOREXANT 5MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Suvorexant" as an intervention, any sponsor and status, largest first.
- The Effects of Orexin Antagonism on Fear Extinction in PTSDPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT06788522 · 40,120 participants (planned) · Start Jul 1, 2026 · Primary completion Mar 1, 2032
Drug: Suvorexant; Placebo · For: Insomnia; PTSD
Sites: San Francisco, California; Charleston, South Carolina
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01097616 · 1,023 participants · Start May 5, 2010 · Primary completion Sep 9, 2011
Drug: Suvorexant High Dose (HD); Suvorexant Low Dose (LD) and 1 more · For: Primary Insomnia
- Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01097629 · 1,020 participants · Start May 3, 2010 · Primary completion Nov 8, 2011
Drug: Suvorexant High Dose (HD); Suvorexant Low Dose (LD) and 1 more · For: Primary Insomnia
- A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT01021813 · 781 participants · Start Dec 10, 2009 · Primary completion May 17, 2011
Drug: Suvorexant; Dose-matched Placebo to Suvorexant · For: Insomnia
- A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06655883 · 300 participants (planned) · Start Oct 9, 2025 · Primary completion Jun 24, 2027
Drug: Suvorexant; Placebo · For: Insomnia
Sites: Garden Grove, California; New Haven, Connecticut; Bradenton, Florida · 13 sites in all
- Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT02750306 · 285 participants · Start May 23, 2016 · Primary completion Sep 30, 2018
Drug: Suvorexant; Placebo · For: Sleep Initiation and Maintenance Disorders; Alzheimer Disease
- Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00792298 · 254 participants · Start Nov 5, 2008 · Primary completion Dec 26, 2009
Drug: Suvorexant; Dose-matched Placebo to Suvorexant · For: Primary Insomnia
- Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related DrinkingPivotal-lookingRecruiting
Ohio State UniversityAcademic, hospital or other
NCT07214207 · 250 participants (planned) · Start Dec 4, 2025 · Primary completion Sep 2030
Drug: Suvorexant 10 mg · For: Alcohol Use Disorder
Sites: Columbus, Ohio
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,050
- nightmare743
- somnolence738
- insomnia688
- abnormal dreams603
- headache549
- feeling abnormal489
- nausea395
- no adverse event389
- hallucination380
- fatigue365
- dizziness341
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 13 |
| 2015 | 2,481 |
| 2016 | 2,499 |
| 2017 | 2,016 |
| 2018 | 1,159 |
| 2019 | 926 |
| 2020 | 783 |
| 2021 | 714 |
| 2022 | 600 |
| 2023 | 602 |
| 2024 | 492 |
| 2025 | 417 |
| 2026 | 329 |
Recalls
2 FDA enforcement reports for this application.
Jul 21, 2025 · Class II · Ongoing
Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Belsomra (Suvorexant)
2024 spending
$150M
Beneficiaries
77,098
315,401 claims
Per beneficiary
$1,948
$14.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $104,140,127 |
| 2021 | $114,695,562 |
| 2022 | $130,017,868 |
| 2023 | $161,202,978 |
| 2024 | $150,180,015 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis.
Kishi T, Ikuta T, Citrome L, et al. · Transl Psychiatry 2025 · Comparative Study, Network Meta-Analysis
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS.
Lucey BP, Liu H, Toedebusch CD, et al. · Ann Neurol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H, O'Leary B, Adena M, et al. · J Manag Care Spec Pharm 2021 · Comparative Study, Network Meta-Analysis
- Pharmacotherapies for sleep disturbances in dementia.
McCleery J, Sharpley AL · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Pharmacological and non-pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review.
Blackman J, Swirski M, Clynes J, et al. · J Sleep Res 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.